Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

AtaiBeckley Inc

ATAI ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: HOLD

Last Close

$7.38

▼ -0.54%

Market Cap $2.74B · Vol 898.32K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.74B

Mid Cap

Div Yield

N/A

EPS Growth

+26.32%

YoY

RSI (14)

70.83

Momentum

Beta

1.55

vs Market

52W High

$7.45

0.94% below

52W Low

$3.27

125.69% above

Volume

898.32K

Avg 2.79M

P/B

6.70

Price-to-book

ROE

N/A

Return on equity

Free Float

96.86%

Public shares

Shariah Compliance8 STANDARDS

✗ AtaiBeckley Inc (ATAI) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ATAI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.65%

+3.43%

+70.44%

+90.21%

YTD

+80.44%

+68.11%

+352.76%

-50.27%

Financials & Valuation

TTM · Annual

Total Revenue	$4.09M
Net Income	$-660,147,000.00
Revenue Growth (YoY)	+137.00%
Gross Margin	100.00%
Operating Margin	-2,720.98%
Net Profit Margin	-16,144.46%
ROE	N/A
ROA · ROIC	-291.90% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	226.59
P/B	6.70
P/FCF	N/A
EPS Growth	+26.32%
Outstanding Shares	370.86M

Technical Indicators

50-Day SMA	$6.07
200-Day SMA	$4.52
RSI (14)	70.83
Beta	1.55
52-Week High	$7.45
52-Week Low	$3.27

Volume Today	898.32K
Avg Daily Volume (30D)	2.79M
Relative Volume	0.32x
Volatility (10D)	8.03
Volatility (30D)	91.99
Free Float	96.86%

Analyst Consensus

HOLD

Current Price $7.38

Mean Target $9.84

52W Low$3.27 52W High$7.45

Current

Target

$3.27 $7.45

Current Analyst target

+33.28% upside potential · 14 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0107FR4D5

ISINUS04650F1012

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.09% ONC BeOne Medicines AG +1.44% RVMD Revolution Medicines Inc -1.07% 068270.KS Celltrion Inc -0.93% ABVX Abivax SA -2.75%

Company Profile

AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.